公开(公告)号：US20160038607A1

公开(公告)日：2016-02-11

申请号：US14765620

申请日：2014-02-04

Applicant: UNIVERSITY OF NOTRE DAME DU LAC

Inventor： Zihni Basar BILGICER ,  Jonathan ASHLEY ,  Tanyel KIZILTEPE-BILGICER ,  Jared STEFANICK ,  Nathan J. ALVES

IPC: A61K47/48 ,  A61K38/07 ,  A61K38/05 ,  A61K9/127

CPC classification number: A61K38/07 ,  A61K9/0014 ,  A61K9/0019 ,  A61K9/008 ,  A61K9/1271 ,  A61K9/2054 ,  A61K9/4858 ,  A61K38/05 ,  A61K47/542 ,  A61K47/62 ,  A61K47/6911

Abstract: The invention provides pharmaceutical compositions and method of using the compositions, wherein the compositions comprise liposomes or micelles that contain one or more targeting peptides and/or anticancer drugs. In various embodiments, the components of the liposomes can include a) a phospholipid and optionally a lipid that is not a phospholipid; b) a pegylated lipid; c) a peptide-ethylene glycol (EG)-lipid conjugate wherein the peptide is a targeting ligand, and d) one or more drug-conjugated lipid, encapsulated drugs, or a combination thereof. The peptide-EG-lipid conjugate can be, for example, a compound of Formula (I) or Formula (II). The ethylene glycol (EG) segments of the peptide-EG-lipid conjugate can be, for example, EG6 to about EG36; and the EG segment can be conjugated to one or more lysine moieties.

Abstract translation: 本发明提供药物组合物和使用组合物的方法，其中组合物包含含有一种或多种靶向肽和/或抗癌药物的脂质体或胶束。 在各种实施方案中，脂质体的组分可以包括a）磷脂和任选的不是磷脂的脂质; b）聚乙二醇化脂质; c）肽 - 乙二醇（EG） - 脂质缀合物，其中所述肽是靶向配体，和d）一种或多种药物结合的脂质，包封的药物或其组合。 肽-EG-脂质缀合物可以是例如式（I）或式（II）的化合物。 肽-EG-脂质缀合物的乙二醇（EG）片段可以是例如EG6至约EG36; 并且EG区段可以与一个或多个赖氨酸部分缀合。

公开(公告)号：US20220218839A1

公开(公告)日：2022-07-14

申请号：US17465418

申请日：2021-09-02

Applicant: University of Notre Dame du Lac

Inventor： Zihni Basar BILGICER ,  Nathan J. ALVES

IPC: A61K47/68 ,  C07K16/28 ,  C07K16/00 ,  G01N33/531 ,  A61K31/337 ,  G01N33/532 ,  G01N33/533 ,  G01N33/543

Abstract: A method of crosslinking a hetero-bifunctional photo crosslinking compound to an immunoglobulin having at least one heterocyclic photo reactive group and at least one non-photo reactive group where the non-photo reactive group is coupled to an effector molecule and the photo reactive group is coupled to the nucleotide binding site of an immunoglobulin. Alternatively, the photo crosslinker contains an orthogonal reactive group such as a thiol, which can be coupled to an effector molecule or functionalized ligand.

公开(公告)号：US20190328896A1

公开(公告)日：2019-10-31

申请号：US16450615

申请日：2019-06-24

Applicant: University of Notre Dame du Lac

Inventor： Zihni Basar BILGICER ,  Nathan J. ALVES

IPC: A61K47/68 ,  C07K16/00 ,  C07K16/28 ,  G01N33/531 ,  G01N33/532 ,  G01N33/533 ,  G01N33/543 ,  A61K31/337

Abstract: A method of crosslinking a hetero-bifunctional photo crosslinking compound to an immunoglobulin having at least one heterocyclic photo reactive group and at least one non-photo reactive group where the non-photo reactive group is coupled to an effector molecule and the photo reactive group is coupled to the nucleotide binding site of an immunoglobulin. Alternatively, the photo crosslinker contains an orthogonal reactive group such as a thiol, which can be coupled to an effector molecule or functionalized ligand.

公开(公告)号：US20180177810A1

公开(公告)日：2018-06-28

申请号：US15878295

申请日：2018-01-23

Applicant: University of Notre Dame du Lac

Inventor： Zihni Basar BILGICER ,  Tanyel KIZILTEPE BILGICER ,  Jonathan Darryl ASHLEY ,  Jared Francis STEFANICK ,  Nathan J. ALVES ,  Michael W. HANDLOGTEN

IPC: A61K31/704 ,  A61K51/04 ,  A61K31/351 ,  A61K47/69 ,  A61K47/62 ,  A61K9/107

CPC classification number: A61K31/704 ,  A61K9/1075 ,  A61K31/351 ,  A61K47/62 ,  A61K47/6907 ,  A61K47/6909 ,  A61K51/0455

Abstract: Embodiments provide systems, methods, and compositions for nanoparticle-based drug delivery to target cells or tissues. A drug delivery system may include a nanoparticle with a targeting component and a therapeutic component. The nanoparticle may have a predetermined number or valence of targeting molecules for multivalent interaction with a target cell or tissue. Binding of the targeting molecules to the target cell may result in receptor-mediated uptake of the nanoparticle by the target cell. The therapeutic component may be subsequently released within an endocytic vesicle of the target cell. Nanoparticle-based drug delivery systems as described herein may provide improved efficacy and/or reduced toxicity.